tamoxifen / P-gp Cancer Research Results

Tam, tamoxifen: Click to Expand ⟱
Features:
Tamoxifen is an endocrine anti-hormone drug used to treat breast cancer and other tumours. Tamoxifen is a hormone therapy that treats or prevents hormone receptor-positive breast cancer.

Tamoxifen (TAM; brands include Nolvadex, Soltamox) — an oral selective estrogen receptor modulator (SERM) used primarily for ER+ breast cancer treatment and risk-reduction. Acts as an estrogen receptor antagonist in breast tissue, with partial agonist effects in other tissues.

Primary mechanisms (conceptual rank):
1) ER antagonism in breast → ↓ estrogen-driven transcription/proliferation
2) Prodrug activation to endoxifen (CYP2D6-dependent) → clinical response modulation
3) Cell-cycle arrest + apoptosis downstream of ER blockade (context-dependent)
4) Tumor microenvironment / growth factor cross-talk modulation (e.g., IGF signaling; context-dependent)

Bioavailability / PK relevance: Long half-life; highly protein-bound; hepatic metabolism. Conversion to active metabolite endoxifen depends in part on CYP2D6 activity and interacting drugs. :contentReference[oaicite:0]{index=0}

In-vitro vs oral exposure: Many non-ER “off-target” cytotoxic mechanisms (e.g., lysosomal/mitochondrial disruption) are reported at higher concentrations than typical clinical free-drug exposure; clinically dominant mechanism is ER modulation in ER+ disease. :contentReference[oaicite:1]{index=1}

Clinical evidence status: Established standard therapy and prevention option for ER+ breast cancer; labeling includes serious risks (uterine malignancies and thromboembolic events).

Tamoxifen — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Estrogen Receptor (ERα) transcriptional program ↓ (primary; ER+) ↔ / ↑ (tissue-dependent partial agonism) R/G Antiestrogen growth blockade Core mechanism in ER+ breast cancer; antagonist in breast, partial agonist in endometrium/bone context. :contentReference[oaicite:3]{index=3}
2 Endoxifen activation (CYP2D6-dependent) ↑ efficacy with adequate activation ↔ G Active metabolite exposure Tamoxifen is a prodrug; CYP2D6 affects endoxifen levels and may affect outcomes (drug interactions can matter). :contentReference[oaicite:4]{index=4}
3 Cell cycle (G1 checkpoint; cyclin/CDK) ↓ proliferation (ER+) ↔ G Cytostatic growth arrest Downstream of ER blockade; strongest in hormone-dependent contexts. :contentReference[oaicite:5]{index=5}
4 Apoptosis ↑ (context-dependent) ↔ G Tumor cell death in responsive settings Typically secondary to sustained estrogen deprivation/ER antagonism; variable by tumor biology. :contentReference[oaicite:6]{index=6}
5 PI3K/AKT/mTOR cross-talk ↔ / ↓ (context-dependent) ↔ R/G Growth-factor pathway interplay Common resistance axis in endocrine therapy; not tamoxifen’s primary biochemical target. :contentReference[oaicite:7]{index=7}
6 ROS ↔ / ↑ (high concentration only) ↔ P/R Not a dominant on-target axis Oxidative/mitochondrial effects are reported mainly in vitro at higher concentrations than typical free systemic exposure.
7 NRF2 ↔ ↔ R/G No primary modulation Not a canonical tamoxifen mechanism.
8 HIF-1α ↔ ↔ G No primary role Any hypoxia-axis effects are indirect and model-dependent.
9 Ferroptosis ↔ (not established) ↔ R/G Not canonical Not an established primary mechanism for tamoxifen.
10 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a dominant on-target axis.
11 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Risk + interactions + resistance Key constraints include uterine malignancy and thromboembolic risks (esp. prevention setting), CYP2D6-dependent activation/interaction issues, and endocrine resistance. :contentReference[oaicite:8]{index=8}

TSF legend: P: 0–30 min (receptor binding); R: 30 min–3 hr (acute transcriptional signaling shifts); G: >3 hr (cell-cycle/apoptosis phenotypes)
P-gp, permeability-glycoprotein: Click to Expand ⟱
Source:
Type:
P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is a membrane protein that plays a crucial role in the transport of various substances across cellular membranes. It is part of the ATP-binding cassette (ABC) transporter family.
P-glycoprotein is often overexpressed in a variety of cancers, including breast cancer, lung cancer, leukemia, and ovarian cancer.

- The overexpression of P-glycoprotein (P-gp), is widely considered as an important reason for the MDR (multidrug resistance).
Scientific Papers found: Click to Expand⟱
926- QC,  PacT,  doxoR,  Tam,    Bioenhancers from mother nature and their applicability in modern medicine
- Review, Nor, NA
*BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, P-gp↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Barriers & Transport ⓘ

P-gp↓, 1,  

Drug Metabolism & Resistance ⓘ

BioEnh↑, 6,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioEnh↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: P-gp, permeability-glycoprotein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:189  Target#:232  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page